[{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Sleep","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Not Applicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Not Applicable"},{"orgOrder":0,"company":"Tilray","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Montelukast Sodium","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Tilray \/ Tilray","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Tilray"},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tilray \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Tilray

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Tilray's oral solution THC10:CBD10 medical cannabis extract is approved for medical use in Portugal for various medical conditions including chronic pain, nausea and spasticity.

                          Brand Name : THC10:CBD10

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 24, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.

                          Brand Name : CBD VersaFilm

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 06, 2023

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : IntelGenx

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support patients through their medical cannabis journey.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 25, 2022

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : CBN, or cannabinol, is derived from THC and is known to help improve the duration and quality of sleep, CBN-dominant oil is carefully formulated with 30mg CBN per mL and 10mg THC per mL (in a 50mL bottle).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 07, 2022

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Company's Fast-Acting Oral Strips contain Cannabinoids absorb directly into the bloodstream provide patients with a fast-acting, convenient, and precise dosing experience for relief from a range of conditions.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 02, 2021

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Aphria

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank